RESULTS:
From 1982 to 2015, a total of 670 postmarketing cases had been reported via pharmacovigilance, for an overall reporting rate of approximately one ADR per 3900 administered standard doses. Of these cases, 343 involved ADRs considered clinically relevant risks (33 thromboembolic complications, 97 inhibitor formation, 110 hypersensitivity or allergic reactions) or potential risks (103 suspected virus transmissions) for Humate-P. Most thromboembolic complications occurred in patients undergoing surgery or with other known risk factors. Inhibitor formation occurred mostly in patients with hemophilia A (24 cases were high titer). Most patients with hypersensitivity or allergic reactions had VWD. None of the reported suspected virus transmission cases were confirmed to be associated with Humate-P. Reported results of companysponsored studies showed a low incidence of adverse events possibly or probably related to Humate-P.
CONCLUSIONS:
More than 33 years of pharmacovigilance data continue to support the safety of Humate-P.
H emophilia A and von Willebrand disease (VWD) are characterized, respectively, by deficiencies in Factor VIII (FVIII) and von Willebrand factor (VWF). 1 Historically, these conditions have largely been managed with clotting factor replacement therapy to restore hemostasis.
Plasma-derived therapies have been associated with virus transmission, but since 1987 no transmissions have been confirmed. 2, 3 Haemate-P/Humate-P (hereafter referred to as Humate-P) is a pasteurized human plasma-derived concentrate that contains both FVIII and a near-normal spectrum of VWF multimers. 4 It was the first product developed to treat these disorders with a dedicated virus reduction step. It has a high proportion of highmolecular-weight VWF multimers known to be important in hemostasis compared with other commercially available FVIII and VWF concentrates; furthermore, the ratio of VWF to FVIII is approximately 2.4:1, allowing adjustment of VWF levels without raising FVIII to levels thought to be thrombogenic. [5] [6] [7] The multimer profile in Humate-P is similar to that in normal plasma. 6 Humate-P was developed by Behringwerke, which subsequently became part of CSL Behring. It was initially licensed in Germany in 1982 and subsequently approved in the United States in 1986 for the management of bleeding in patients with hemophilia A and later for VWD. Several publications have documented the efficacy of Humate-P in VWD and hemophilia A. 4, [8] [9] [10] [11] [12] [13] The manufacturing process for Humate-P includes multiple sequential steps that reduce the risk of virus transmission: 1) cryoprecipitation; 2) Al(OH) 3 adsorption, glycine precipitation, and NaCl precipitation; 3) heat treatment at 608C for 10 hours in aqueous solution (i.e., pasteurization); and 4) lyophilization. Together, these processing steps achieve total cumulative virus reduction ranging from 6.0 to 11.7 log or more.
14 Pasteurization is the most important step in this process because it is highly effective at inactivating a broad range of viruses that could potentially be present in plasma. The heatlabile FVIII molecule is stabilized during the heat treatment process by the addition of glycerin and sucrose. In 1988, citrate was replaced with antithrombin III and heparin in buffer solutions used during the purification process. This further enhanced stabilization of FVIII and increased yields. Beyond disease transmission, thromboembolic complications are a concern with FVIII/VWF products, and inhibitor formation is a well-known risk in hemophilia A patients treated with FVIII concentrates. Furthermore, as with any biologic agent administered intravenously, hypersensitivity is a possibility.
Here, we reviewed the safety profile of Humate-P based on 33 years of spontaneous postmarketing reports of potential adverse drug reactions (ADRs) and the medical literature, with a focus on clinically relevant and potential risks associated with FVIII and VWF products. This review provides clinicians with essential safety data to inform the choice between Humate-P and newer recombinant factor products.
MATERIALS AND METHODS

Pharmacovigilance reporting
Reports of potential ADRs were compiled from the date of first marketing authorization (June 1982) to November 30, 2015 , as part of routine pharmacovigilance at CSL Behring. The data included spontaneous ADR reports, reports of adverse events (AEs) from postmarketing trials and regulatory agencies (including US MedWatch), and AEs reported in the scientific literature. Details, including the date, country of origin, patient age and sex, indication, Humate-P dose, concomitant blood products, manifestations, and event outcomes, were recorded for each report, if available. In addition, if the blood product was not specified, attempts were made to document which FVIII concentrates were used.
A narrative description of the case was obtained whenever possible. Follow-up information was queried when relevant information was missing from the initial report; however, missing information was not always available. The coding used for this analysis was the Medical Dictionary for Regulatory Activities (MedDRA, Version 18.1). ADRs were classified as serious or nonserious according to the standard definition of a serious event (i.e., an event that resulted in death, was life-threatening, required hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was medically important).
The total quantity of Humate-P distributed worldwide, including the United States, was determined from CSL Behring commercial records (data were only available since 1990). The exact number of patients administered Humate-P during the reporting period is not known; therefore, the following assumptions were made to calculate patient exposure: for long-term prophylaxis in patients with severe hemophilia A, the usual dose of Humate-P ranges from 20 to 40 international units (IU) per kilogram of body weight, given at conservative intervals of two or three times weekly. Based on a mean body weight of 70 kg and using a dose of 30 IU, this equates to an estimated standard dose of approximately 2100 IU (rounded down to an estimated dose of 2000 IU based on the vial presentations). Assuming that this dose is given twice weekly (particularly for prophylaxis in severe VWD), an annual dose equates to approximately 208,000 IU per patient, representing approximately 25,000 patient-years of exposure.
A detailed review was performed on ADRs considered to be clinically relevant during use of Humate-P (i.e., thromboembolic complications, FVIII or VWF inhibition, hypersensitivity or allergic reactions) or those that were potential risks (i.e., suspected virus transmission). These cases were identified using standardized MedDRA queries (SMQs), high-level group terms, high-level terms (HLTs), and preferred terms (PTs) within the MedDRA dictionary. Thromboembolic complications were identified in the pharmacovigilance database using the SMQs "embolic event" or "thrombotic event" (narrow). FVIII or VWF inhibition was identified using the SMQ "lack of efficacy/ effect" (narrow), as well as the specified PT inhibitor or antibody development (including the PTs FVIII inhibition, inhibiting antibodies, and VWF inhibition). Hypersensitivity or allergic reactions were identified using the SMQ "hypersensitivity" (narrow), which included anaphylactic reaction, anaphylactic shock, anaphylactoid reaction, hypersensitivity, angioedema, and related terms. Suspected virus transmission was identified in the database using the high-level group term "viral infectious disorder"; the HLT "infectious transmission"; the HLT "virus identification and serology"; or PTs associated with hepatitis A, hepatitis B, hepatitis C, human immunodeficiency virus (HIV), parvovirus, cytomegalovirus, and Epstein-Barr virus.
Each identified case underwent a medical assessment to confirm that it met the case definition of either an important or potential risk. The remaining cases not considered to be clinically significant risks for analysis were summarized as a group.
Literature review
Literature searches were conducted using Embase and PubMed. The goal was to identify original, English language articles published between January 1, 1980, and November 18, 2015 , that reported on Humate-P and blood clotting FVIII inhibitor or thromboembolism or allergic reaction/hypersensitivity or virus transmission. For Embase, the following search strategy was used: Humate-P or Haemate-P or Haemate and thromboembolism or "embolism and thrombosis" or virus transmission or disease transmission or "allergic reaction" or hypersensitivity or inhibition or inhibitor or (infection or viruses or virus or viral and transmission). For PubMed, we used the following search terms: Haemate-P or Humate-P or Haemate and "embolism and thrombosis" or allergic reaction or "factor VIII/antagonists and inhibitors" or inhibition or inhibitor or (viral or virus or viruses or infection* and transmission).
Once relevant publications were identified, the authors, methods, and periods were examined to eliminate any duplicate data from multiple reports. Data were extracted from these reports regarding the number and age of patients infused with Humate-P, the specific type of VWD deficiency and indication, the treatment regimen, and the occurrence of AEs, including their reported relation to Humate-P. Only reports with safety data were included, and all reported AEs were included in the analysis regardless of whether a relation to Humate-P could be established.
RESULTS
Pharmacovigilance
The cumulative quantity of Humate-P distributed worldwide since 1990 is more than 5.2 billion IU, corresponding to approximately 2.6 million standard doses and approximately 25,000 patient-years of exposure. During the reporting period from 1982 to 2015, our analysis showed that 670 postmarketing ADR cases were reported, corresponding to an overall reporting rate of one ADR per 3900 administered standard doses. The mean age of patients was 24.6 years, ranging from less than 1 to 91 years. Of the 670 cases, 249 occurred in females and 353 in males (68 cases did not have sex recorded); 13 were reported to have a fatal outcome, none of which was related to administration of Humate-P (Table 1) . Overall, 343 ADRs represented a clinically relevant risk of Humate-P therapy (including 33 cases of thromboembolic complications, 97 cases of inhibitor formation, and 110 cases of hypersensitivity or allergic reactions), and 103 were cases of suspected virus transmission.
Thromboembolic complications
Thromboembolic complications are a concern because they could result from elevation of FVIII levels. As shown in Table 2 , 33 cases were reported in patients treated with Humate-P; this is approximately one case per every 78,787 standard doses administered. In five cases, the brand of FVIII and VWF concentrate was unknown. Mean age was 48 years (range, 5-84 years) with two patients not more than 12 years of age; 19 patients were female, and 14 were male. There were 20 cases of deep venous thrombosis (DVT) and pulmonary embolism (PE), three cardiacrelated thrombosis cases (i.e., coronary artery occlusion and acute myocardial infarction), three transient ischemic attacks or stroke cases, and seven cases with "other" thrombotic complications (Table 2) . Twenty-four of these ADRs occurred in VWD patients, six occurred in patients with hemophilia A, one of whom was receiving immune tolerance induction (ITI). For the remaining three cases, the indication was unknown. In 19 cases, the ADR was associated with surgery, which is a known independent risk factor for DVT or PE. From the available information in these reports, most patients did not receive heparinbased thromboprophylaxis. Further reported independent risk factors for DVT or PE were angiodysplasia (n 5 1), monoclonal gammopathy (n 5 2), and cancer (n 5 3). Additionally, there was a thromboembolic complication in one patient who received a higher-than-prescribed dose.
Inhibitor formation
Inhibitor formation is a well-known risk in hemophilia A patients treated with FVIII concentrates and has also been described generally in Type 3 VWD patients. [15] [16] [17] Upon medical review, 97 reports of inhibitor formation were (Table 3 and Table 4 ). This is approximately one case per 26,804 standard doses. In 33 cases, it was unknown whether Humate-P was used. Among patients with inhibitor formation, the mean age was 18.3 years (range, 0.7 months to 74 years), and 25 patients were not more than 2 years of age. Sixty-nine cases of FVIII inhibitors were reported, including two reported as acquired hemophilia and another with an unknown indication; in 24 cases, the inhibitor was described as high titer (Table 3 ). There were 28 reported cases of inhibitor formation in patients with VWD (Table 4) , with 12 of these patients being female. VWF inhibitors occurred mostly in patients with Type 3 VWD. In six cases, the patient had an associated allergic reaction to the drug.
Hypersensitivity or allergic reactions
Upon medical review, 110 cases related to hypersensitivity or allergic reactions were identified in the Humate-P pharmacovigilance database. This is approximately one case per 23,636 standard doses. The mean age of patients was 32 years (range, 1.7 months-76 years), and 10 patients were not more than 2 years of age. Most patients (64%) had VWD. Events included hypersensitivity (n 5 51), anaphylactic reaction (n 5 22), anaphylactic shock (n 5 3), anaphylactoid reaction (n 5 5), and angioedema (n 5 4). Nineteen of the reported anaphylactic reactions were serious; three of these did not have sufficient details reported to assess a possible relation to Humate-P. Among the three reported patients with anaphylactic shock, the brand of concentrate was unknown in one case and the clinician did not feel the reaction was due to Humate-P in another case. For the remaining hypersensitivity cases, a range of ADRs was reported: urticaria (n 5 40), edema (n 5 20), asthma and/or wheezing or bronchospasm (n 5 20), and impact on the larynx and thus breathing (n 5 10). Based on medical review, six cases were identified that were also associated with inhibitor formation (see details in Table 2 and Table 3 ). Many of the hypersensitivity and anaphylactic cases also reported reactions to other FVIII products or other drugs, and the patients had other allergies.
Suspected virus transmission
Cases of suspected virus transmission are thoroughly followed up with the reporting physician, and, if lot numbers are available, investigation of concerned batches or related plasma pools will occur. We identified 103 cases of potential virus transmission using the PTs associated with hepatitis A, B, and C; HIV; parvovirus; cytomegalovirus; and Epstein-Barr virus. Mean age was 27.3 years (range, 2.3-54 years), and one patient was not more than 2 years of age. Of these, 22 patients were female, and 66 were male (15 cases did not report sex). Fifty-nine cases of potential transmission of hepatitis C were reported. Of these, four cases could not be finally assessed due to insufficient information. In the remaining cases, the use of other plasma-derived products before the introduction of viral inactivation or the use of other blood products not subject to virus reduction steps were the more likely cause of the infection. Also, there was insufficient information to determine whether transmission occurred by modes other than transfusion. There were 17 reports of hepatitis B, three of hepatitis A, and eight of parvovirus infection. A direct link to Humate-P could be excluded based on available laboratory data, evidence regarding the patient's medical history, or a negative polymerase chain reaction test for the concerned batches or the available information was inadequate to form any conclusion. There was one case of cytomegalovirus and two cases of Epstein-Barr virus infections in which no other cause could be found; these are white blood cell-associated viruses not transmitted by plasmaderived products. 18 There were 24 cases of HIV infection, but other causes of infection were identified in all cases. In all cases of suspected virus transmission (except the ones with insufficient information), the causal relation to the product was assessed as unlikely. Among all reports of infections, 33% had used other products or had other causes identified; 31% had received clotting factor products before the introduction of virus reduction steps in manufacturing; 11% had received blood products not subject to virus reduction steps such as red blood cells (RBCs), platelets, or plasma; and 26% had insufficient information or a timing of the infection that did not correlate with Humate-P administration. To date, no confirmed cases of viral or prion transmission have been associated with Humate-P.
Other reported events
To analyze the overall safety profile of Humate-P, all 670 cases were reviewed by respective MedDRA system organ classes, including the 346 cases classified as hypersensitivity, inhibitor, thromboembolic, or viral related. In total, 1730 ADRs were reported (one case could report more than one ADR): most of the ADRs were categorized under general disorders and administration site conditions (266), investigations (221), and skin and subcutaneous tissue disorders (192) . In addition to the ADRs associated with the important or potential risks of Humate-P, the most common MedDRA PTs reported (30) were nausea, chills, drug ineffective, pyrexia, dyspnea, and pruritus ( Fig.  1) . Among the 37 reports of drug ineffective, three cases also included reports of inhibitors. There was also one case of hemolytic anemia thought to be related to an antibiotic and one case of thrombocytopenia with uncertain relation to Humate-P. 
Literature reports
In 2009, Federici 9 reviewed the safety profile of clotting factor concentrates and described the most common AEs as (1) fever, hypersensitivity, and allergic or anaphylactic reactions; 2) inhibitor formation; 3) thromboembolic events; and 4) blood-borne infections. The authors stated that fever, hypersensitivity, and allergic or anaphylactic reactions were observed only rarely with all clotting factor concentrates and that these types of reactions are a potential concern with any plasma-derived protein.
Inhibitors were noted to be rare in VWD compared with hemophilia and generally limited to Type 3 patients with a large gene deletion. Regarding thromboembolic events, the authors indicated that sustained high plasma levels of FVIII may increase the risk of thrombosis. They suggested that patients be monitored to avoid values more than 150 IU/ dL and that anticoagulation with low-molecular-weight heparin might be reasonable. With available technology in use at that time, the authors estimated that the risk of blood-borne infection is "virtually zero." More recently, the VWD International Prophylaxis Study Group presented retrospective data on VWF and FVIII concentrate prophylaxis in patients with VWD. Data were presented on 59 patients, most of whom were Type 3, and Humate-P was used in 77% of cases. There were no cases of thromboembolism reported. 19 Another study of continuous infusion of clotting factor concentrates that included Humate-P, among other products, reported no AEs in 46 patients. 20 Reports of thromboembolic events occurring in other published studies have been captured in our reported ADRs and analyzed. 14, 21 In addition, our ADR database captured three reports of transient neutralizing antibodies developing in VWD patients receiving prophylaxis with Humate-P and a report of anaphylactoid reactions to both Humate-P and Willate. [22] [23] [24] Initial studies confirmed that
Humate-P does not transmit hepatitis B, and later it was shown that it also does not transmit either hepatitis C or HIV.
4,25
Sponsored studies bleeding despite effective surgical hemostasis. Two other SAEs (sepsis and pyelonephritis) were considered unrelated to treatment. Other commonly reported AEs were nausea (37%), constipation (14%), dizziness (14%), pain (14%), fever (11%), hemorrhage (11%), pruritus (9%), abdominal pain (9%), chest pain (9%), and urinary retention (9%). Six AEs were considered possibly related to Humate-P, including headache (n 5 3), itching (n 5 1), nausea (n 5 1), and dizziness, which were all mild in severity and self-limiting except for one individual who complained of nausea for 30 days. Recently, Miesbach and colleagues 12 reported on a 25-year retrospective observational study of Humate-P in 71 VWD patients. They observed no allergies or transmission of viral infections and only one adverse reaction, a case of PE attributed to incorrect dosing (due to transcription error, the patient received three times the desired dose). An interim analysis from a prospective, long-term (4 years), observational, pharmacovigilance study of Humate-P in 108 patients (101 with VWD and seven with hemophilia A) showed that one African American hemophilia patient developed a low-titer inhibitor that was successfully eliminated by ITI. There were no reported cases of thromboembolic events or viral transmission. 28, 29 In a small study of ITI with Humate-P, no AEs were reported among the three patients treated. 30 
DISCUSSION
This article reviews the safety of Humate-P based on 33 years of pharmacovigilance. Humate-P was initially widely used for treating hemophilia A, but, in recent years, it has been used more for VWD. Humate-P has the distinction of being on the market longer than any other product for the treatment of bleeding disorders. Pharmacovigilance is based not only on voluntary reporting of potential adverse reactions by physicians and others but also on follow-up of all reports in clinical trials and the medical literature. It encompasses collection and assessment of safety data from all sources. While the voluntary reporting system has the disadvantage of depending on a physician's and patient's willingness to report ADRs, not all reported events are confirmed to have a causal relation to the drug, indicating that in fact a wide net has been cast. We must, however, concede that ADRs are historically underreported. 31 However, SAEs are more likely to be reported. 32 In addition, in the past 15 years, additional postmarketing studies with Humate-P have been performed for marketing authorization in the United States. 8, 10, 11, 13, 26 In these trials, all AEs were captured prospectively as opposed to ADRs in spontaneous reporting. This coincides with the evolution of pharmacovigilance to a more proactive approach to identify safety signals with additional regulatory initiatives by the US Food and Drug Administration (sentinel system) and European Medicines Agency.
32,33
The risk of thrombosis in treated patients relates to elevated FVIII in addition to other comorbidities. 34, 35 The pharmacovigilance data show that, compared with the overall number of treated patients, only a small number of thromboembolic events occurred, with most associated with ITI, surgery, or other prothrombotic conditions. Gill and Mannucci 36 addressed the concern related to the risk of thromboembolic events in those with high levels of VWF or FVIII. They indicated that there is no evidence suggesting the risk of thromboembolic complications is significantly different between the various commercially available products. Furthermore, the authors indicated that many VWD patients treated with concentrate will develop high levels of FVIII and/or VWF, but most will not suffer thromboembolic complications. One could speculate that Humate-P with the lowest relative FVIII content should have a lower risk of thrombosis. Nevertheless, they support current guidelines recommending that VWD patients have their FVIII and VWFR:RCo levels monitored daily while being treated with VWF or FVIII concentrates for surgery. In addition, routine thromboprophylaxis should be considered, particularly if other prothrombotic conditions are present. Pharmacovigilance reports of inhibitors or hypersensitivity are relatively low for intravenously administered and FVIII or VWF products, whether plasma derived or recombinant. A recent randomized study of plasmaderived FVIII concentrate versus recombinant FVIII showed a much lower rate of inhibitor formation with plasma-derived products. 37 To date, there have been no confirmed reports of disease transmission with Humate-P. Not all cases reported sufficient detail for a thorough assessment, but, in most cases, other more likely possible causes of transmission were identified. Had there been a breakdown in the virus inactivation of Humate-P, one would have expected a cluster of cases in a particular batch. Pharmacovigilance data are checked for such incidents, and no clusters have been detected for Humate-P.
A limitation of this review is that, in many cases, the administered FVIII/VWF product could not be identified. If the report came from a country in which Humate-P was marketed, the process obligates the clinical safety or pharmacovigilance group to follow-up on ADR reports when the brand of FVIII or VWF was unknown or not specified. In some cases, patients were treated with more than one brand of product, and it was impossible to determine which product was related to the ADR.
Postmarketing safety studies such as the one reported here collect data on patients who would not ordinarily be included in clinical trials, rare events, and provider concerns. The additional data from these studies are becoming more frequently reported by other companies 33 and us. 38 events, inhibitor formation, and hypersensitivity reactions at approximately one in 15,476 cases or 101 patient-years. Humate-P has proven, through more than 30 years of clinical experience, to have a remarkable safety record that should be considered when making product choices for patients with hemophilia A or VWD. 
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